Drugs / MORF-057
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04580745 | Sep 2020 → Mar 2021 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 23 trials · 1 met primary · 1 missed | ||||||
| Phase 2 | NCT06226883 | Jul 2024 → Sep 2028 expected | Crohn disease | Eli Lilly and Company | Recruiting | No outcome recorded |
| Phase 2 | NCT05611671 | Nov 2022 → Nov 2024 overdue | ulcerative colitis | Eli Lilly and Company | Active not recruiting | Missed primary |
| Phase 2 | NCT05291689 | Apr 2022 → Oct 2023 | ulcerative colitis | Eli Lilly and Company | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MORF-057 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05611671 ↗ |
| Action | Inhibit | “designed to selectively inhibit integrin α4β7” NCT05291689 ↗ |
| Modality | Small molecule | “MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.” NCT05291689 ↗ |
| Route | Oral | “Oral MORF-057” NCT04580745 ↗ |